MNCs Warn S. Korea Of More New-Drug Withholding To Protest Low Prices
This article was originally published in PharmAsia News
Executive Summary
Multinational drug companies are letting South Korea authorities know that unless the country adjusts its low drug prices, they will step up their recent practice of withholding new drugs from the $18.8 billion market.